Based on the Beam Therapeutics Inc stock forecast from 9 analysts, the average analyst target price for Beam Therapeutics Inc is USD 53.05 over the next 12 months. Beam Therapeutics Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Beam Therapeutics Inc is Slightly Bearish, which is based on 3 positive signals and 6 negative signals. At the last closing, Beam Therapeutics Inc’s stock price was USD 28.48. Beam Therapeutics Inc’s stock price has changed by +8.12% over the past week, +3.90% over the past month and -24.11% over the last year.
No recent analyst target price found for Beam Therapeutics Inc
No recent average analyst rating found for Beam Therapeutics Inc
Company Overview Beam Therapeutics Inc
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts. Read Less
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-t...Read More
Frequently Asked Questions About Beam Therapeutics Inc (BEAM) Stock
Based on ratings from 9 analysts Beam Therapeutics Inc's stock is Buy . Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 11 buy, sell and 8 hold ratings.
Unfortunately we do not have enough data on BEAM's stock to indicate if its a good dividend stock.
Based on targets from 9 analysts, the average taret price for BEAM is USD 53.05 over the next 12 months. The maximum analyst target price is USD 80 while the minimum anlayst target price is USD 24.
BEAM stock's Price/Earning ratio is -99,999.99.
Our analysis grades BEAM stock's Price / Earning ratio at A+. This means that BEAM stock's Price/Earning ratio is above 2.000000000000002% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this BEAM may be undervalued for its sector.
The last closing price of BEAM's stock was USD 28.48.
The most recent market capitalization for BEAM is USD 2.20B.
Based on targets from 9 analysts, the average taret price for BEAM is projected at USD 53.05 over the next 12 months.
This means that BEAM's stock price may go up by +86.28% over the next 12 months.
We can't find any ETFs which contains Beam Therapeutics Inc's stock.
As per our most recent records Beam Therapeutics Inc has 483 Employees.
Beam Therapeutics Inc's registered address is 238 Main Street, Cambridge, MA, United States, 02142-1016.
You can get more information about it from Beam Therapeutics Inc's website at https://beamtx.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Negative earnings
The company had negative total earnings in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Beam Therapeutics Inc (BEAM) Stock
Based on ratings from 9 analysts Beam Therapeutics Inc's stock is Buy . Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 11 buy, sell and 8 hold ratings.
Unfortunately we do not have enough data on BEAM's stock to indicate if its a good dividend stock.
Based on targets from 9 analysts, the average taret price for BEAM is USD 53.05 over the next 12 months. The maximum analyst target price is USD 80 while the minimum anlayst target price is USD 24.
BEAM stock's Price/Earning ratio is -99,999.99.
Our analysis grades BEAM stock's Price / Earning ratio at A+. This means that BEAM stock's Price/Earning ratio is above 2.000000000000002% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this BEAM may be undervalued for its sector.
The last closing price of BEAM's stock was USD 28.48.
The most recent market capitalization for BEAM is USD 2.20B.
Based on targets from 9 analysts, the average taret price for BEAM is projected at USD 53.05 over the next 12 months.
This means that BEAM's stock price may go up by +86.28% over the next 12 months.
We can't find any ETFs which contains Beam Therapeutics Inc's stock.
As per our most recent records Beam Therapeutics Inc has 483 Employees.
Beam Therapeutics Inc's registered address is 238 Main Street, Cambridge, MA, United States, 02142-1016.
You can get more information about it from Beam Therapeutics Inc's website at https://beamtx.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for BEAM !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
